


pFusionRed-zyxin vector

The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.



For vector sequence, please visit our Web site at http://www.evrogen.com/products/vectors.shtml

Location of features

P_{CMV IE}: 1-589 Enhancer region: 59-465 TATA box: 554-560 Transcription start point: 583 Zvxin: 636-2348 FusionRed: 2370-3068 SV40 early mRNA polyadenylation signal Polyadenylation signals: 3221-3226 & 3250-3255 mRNA 3' ends: 3259 & 3271 f1 single-strand DNA origin: 3318-3773 Bacterial promoter for expression of Kan^r gene -35 region: 3835-3840; -10 region: 3858-3863 Transcription start point: 3870 SV40 origin of replication: 4114-4249 SV40 early promoter Enhancer (72-bp tandem repeats): 3947-4018 & 4019-4090 21-bp repeats: 4094-4114, 4115-4135 & 4137-4157 Early promoter element: 4170-4176 Major transcription start points: 4166, 4204, 4210 & 4215 Kanamycin/neomycin resistance gene

Neomycin phosphotransferase coding sequences: Start codon (ATG): 4298-4300; Stop codon: 5090-5092 G->A mutation to remove Pst I site: 4480

Polyadenylation signals: 5328-5333 & 5341-5346 pUC plasmid replication origin: 5677-6320

Product	Cat.#	Size	
pFusionRed-zyxin vector	FP425	20 μ g	
Vector type	mammalian expression vector		
Reporter	FusionRed		
Reporter codon usage	mammalian		
Promoter for FusionRed	P _{CMV IE}		
Host cells	mammalian		
Selection	prokaryotic - kanamycin eukaryotic - neomycin (G418)		
Replication	prokaryotic - pUC ori eukaryotic - SV40 ori		
Use	red fluorescent labeling of zyxin		

Vector description

pFusionRed-zyxin is a mammalian expression vector encoding FusionRed-zyxin fusion protein. The vector can be used for fluorescent labeling of zyxin in living cells.

FusionRed codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al. 1996]. Human zyxin is fused to the FusionRed N-terminus.

pFusionRed-zyxin vector can be used as a source of FusionRed-zyxin hybrid sequence. The vector backbone contains unique restriction sites that permit its excision and further insertion into expression vector of choice. **Note:** The plasmid DNA was isolated from dam⁺-methylated *E.coli*. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam⁻ host and make fresh DNA.

The vector backbone contains immediate early promoter of cytomegalovirus ($P_{CMV \, IE}$) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in *E. coli*, and f1 origin for single-stranded DNA production. SV40 polyadenylation signals (SV40 poly A) direct proper processing of the 3'-end of the reporter mRNA.

SV40 early promoter (P_{SV40}) provides neomycin resistance gene (Neo^r) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kan^r) in *E. coli.* Kan^r/Neo^r gene is linked with herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signals.

Expression in mammalian cells

pFusionRed-zyxin vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the FusionRed-zyxin fusion in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman 1985].

Propagation in E. coli

Suitable host strains for propagation in *E. coli* include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/ColE1. The vector confers resistance to kanamycin (30 μ g/ml) to *E. coli* hosts. Copy number in *E. coli* is about 500.

References

Gorman, C. (1985). "High efficiency gene transfer into mammalian cells." In: DNA cloning: A Practical Approach, Vol. II. Ed. by Glover. (IRL Press, Oxford, U.K.) Pp. 143–190.

Haas, J. et al. (1996) "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol, 6 (3): 315–324 / pmid: 8805248

Notice to Purchaser:

FusionRed-related materials (also referred to as "Products") are intended for research use only.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The Products are covered by European Pat. 1994149 and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License #001: http://www.evrogen.com/products/Evrogen-FP-license.shtml.